About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
Contact Us
R&D and science
R&D Platform
Pipelines
Products Center
Manufacturing
Subject Recruitment
Expanded Access Policy
Collaborations
Investor Relations
Listing Documents
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Career
Now Hiring
简
|
EN
|
Akeso News
Monthly News
2023-01-16
China NMPA Approved 安尼可® (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC
2022-12-06
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)
2022-11-13
Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China
2022-11-04
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
2022-10-31
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
2022-10-21
Akeso's Ivonescimab(PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC
2022-10-17
Akeso's Cadonilimab (PD-1/CTLA-4 Bi-specific) included in the 2022 CSCO Guidelines as the Top Recommendation for Cervical Cancer Immunotherapy
2022-10-17
Akeso Is Developing Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors
2022-06-29
Akeso’s Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
2022-06-06
Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022
2022-06-06
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) combined with chemotherapy in advanced NSCLC at ASCO 2022
2022-06-06
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) for advanced NSCLC at ASCO 2022
2022-04-26
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody(AK127)at the American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-04-26
Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody(AK131)at the American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-04-26
Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody(AK129)at the American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-03-08
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
2022-03-02
Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer
2022-02-11
AKESO’S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)
2021-11-02
PD-1/VEGF BI-SPECIFIC ANTIBODY (AK112) OBTAINED APPROVAL TO INITIATE A PHASE II CLINICAL TRIAL FOR MONOTHERAPY OR COMBINED CHEMOTHERAPY...
2021-10-22
Akeso, Inc. Doses First Patient in a Clinical Study of Anti-TIGIT Monoclonal Antibody (AK127) in Combination with Cadonilimab (Anti-PD-1/CTLA-4) for Treatment of Advanced or Metastatic Solid Tumors
2021-10-18
Akeso Will Publish Six Latest Research Results at the SITC 2021
2021-10-12
Rapid Advancement of Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
2021-10-11
AK112 (PD-1/VEGF Bi-Specific Antibody) in Combination with AK117 (CD47 Monoclonal Antibody) Obtained Approval to Initiate Clinical Trial for the Treatment of Advanced Malignant Tumors
2021-10-05
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate Clinical Trial for the Treatment of Advanced Triple-Negative Breast Cancer
2021-09-29
Completion of Patient Enrollment for Phase II Clinical Trial of IL-17A Monoclonal Antibody AK111 for Treatment of Moderate-to-Severe Plaque Psoriasis
2021-09-27
IL-4Rα Monoclonal Antibody (AK120) Initiates a Global Phase II Clinical Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis
2021-09-26
Latest Results of a Phase II Clinical Study of PD-1/VEGF Bi-Specific Antibody (AK112) in Combination with Chemotherapy for First-Line Treatment of Advanced NSCLC Published at 2021 CSCO
2021-09-26
Akeso was included in the “Chinese Antibody Drug Companies Innovation TOP 30” by “2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists”
2021-09-24
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
2021-09-23
2021 CSCO | Latest Results of Two Phase II Clinical Studies of Akeso’s PD-1/VEGF Bispecific Antibody (AK112) for Treatment of Lung Cancer and Ovarian Cancer
2021-09-19
Akeso Publishes Updated Results of a Phase II Study of Penpulimab Monoclonal Antibody for Treatment of Metastatic NPC with Progression after Two or More Lines of Chemotherapy at ESMO 2021
2021-09-19
Akeso’s Latest Updates of a Phase Ib/II Trial of AK104 (PD-1/CTLA-4 Bi-Specific Antibody) in Combination with Anlotinib in Patients with PD-L1 Positive and Anti-PD-1/L1 Resistant Advanced NSCLC at ESMO 2021
2021-09-19
Oral Presentation of Mechanism Study of IgG1 Isotype Anti-PD-1 Monoclonal Antibody Penpulimab at ESMO 2021 by Akeso’s CSO, Dr. Baiyong Li
2021-08-27
Akeso, Inc. Works with Pfizer to Conduct a Clinical Research of Cadonilimab (Bi-specific Antibody) with Combination of Axitinib for the First-line Treatment of Advanced / Metastatic Renal Clear Cell Carcinoma
2021-08-24
Akeso’s PD-1/CTLA-4 Bi-Specific Antibody Obtained Approval from the CDE to Submit NDA and has been Granted Priority Review Designation
2021-08-23
New PD-1 Monoclonal Antibody 安尼可® (Penpulimab) Officially for Sale, First Prescriptions Made Nationwide
2021-08-21
Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®)
2021-08-09
Akeso’s Latest Updates on the Clinical Trials of Cadonilimab and 安尼可 ® (Penpulimab) will be Published at ESMO 2021
2021-08-05
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
2021-08-05
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma Accepted by NMPA
2021-08-04
PD-1/CTLA-4 Bi-specific Antibody in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Solid Tumors
2021-08-03
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Initiated Phase III Clinical Trial for First-Line Treatment of Advanced Gastric Cancer, National Researchers’ Conference Successfully Held
2021-07-13
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
2021-07-09
Michael Xi: Anti-PD-1 bi-specific antibodies mark the immuno-oncology era 2.0
2021-07-06
Completed Patient Enrollment of the First Cohort with PD-1/CTLA-4 Bispecific Antibody (AK104) in Combination with CD47 Monoclonal Antibody (AK117) for Treatment of Solid Tumors
2021-07-05
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Cancer
2021-07-02
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for First-Line Treatment of Squamous Non-Small-Cell Lung Cancer Accepted by NMPA
2021-06-30
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
2021-06-21
Akeso among “TOP 10 Chinese Bispecific Antibody Drug Companies” Ranked by BioChina List of China Biopharmaceuticals
2021-06-18
Akeso Dr. Xia Yu and Dr. Wang Zhongmin Win the First “World-Benefiting Pharmaceutical Innovation” Award
2021-06-16
Out-Licensed by Akeso to MSD for US$200 Million, Monoclonal Antibody CTLA-4 Entered Phase III Clinical Trial
2021-06-15
ASCO21 | Latest Updates on Two Akeso’s AK104 (PD-1/CTLA-4 Bispecific Antibody) Clinical Trials
2021-06-11
Akeso Expands Development with New International Center Project Settles in Shanghai
2021-05-24
Akeso Penpulimab Monoclonal Antibody (PD-1) Submitted BLA in the United States
2021-05-20
Latest Updates on the Clinical Trials of AK104, AK112, AK117 and AK105 Published at ASCO 2021
2021-05-18
CD47 Monoclonal Antibody (AK117) Obtained Approval for Phase I/II Clinical Trial for Treatment of Medium- to High-Risk Myelodysplastic Syndromes (MDS)
2021-05-13
Akeso, Inc. Inclusion in the MSCI China Index
2021-05-12
Initiation of Various Clinical Trials of PD-1/VEGF Bispecific Antibody (AK112)
2021-04-28
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Approval to Initiate Phase III Clinical Trial for First-Line Treatment of Advanced Cervical Cancer
2021-04-27
New Level of Production Capacity Expansion Akeso Builds the World’s Largest FlexFactory Platform in Cooperation with Cytiva
2021-03-30
Penpulimab (PD-1) Obtained Breakthrough Therapy Designation from FDA for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma
2021-03-12
Akeso Guangzhou Manufacturing Base Project Phase I Goes into Operation
2021-03-03
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Orphan Drug Designation from FDA of the United States for Treating Cervical Cancer
2020-07-30
Akeso, Inc. Promotes the Deployment of Innovative Pipeline Global Cooperation Appoints Dr. Michael (Chen) Chen as Business Development Vice President
2020-07-03
康方生物董事长兼首席执行官夏瑜女士入选2020福布斯“中国科技女性榜”
2020-05-25
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
2020-05-11
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
2020-04-02
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer